Oral semaglutide has been tested in large human trials, and authorised oral medicines exist for specific conditions. Evidence for one oral product, strength or indication should not automatically be transferred to another.
Still uncertain: Equivalence across oral formulations, strengths, unapproved products or uses outside the authorised indication.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
GLP-1 receptor agonist peptide analogue
Entity type
Peptide analogue / modified peptide
Research focus
Type 2 diabetes; semaglutide also has weight-management evidence in other authorised formulations.
Human evidence
Oral semaglutide now has strong human evidence across obesity and cardiovascular outcomes. OASIS 4 found -13.6% mean weight change with oral semaglutide 25 mg versus -2.2% placebo at week 64, while SOUL showed fewer major cardiovascular events with oral semaglutide in high-risk type 2 diabetes.
Regulatory status
Authorised oral semaglutide products now include Rybelsus for type 2 diabetes and oral Wegovy tablets for adult weight management in current U.S./EU records; exact indication, strength and jurisdiction must be stated.
Main limitations
Equivalence across oral formulations/strengths or use outside the authorised product, population and indication.
Safety
GI adverse effects; risks and contraindications are detailed in authorised product information.
Evidence reviewed
2026-09-18
i
Oral semaglutide now has strong human evidence across obesity and cardiovascular outcomes. OASIS 4 found -13.6% mean weight change with oral semaglutide 25 mg versus -2.2% placebo at week 64, while SOUL showed fewer major cardiovascular events with oral semaglutide in high-risk type 2 diabetes.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Route / formulation boundaryRybelsus, oral Wegovy and injectable semaglutide are not interchangeable formulations. Trial doses and currently labelled commercial tablet strengths must be kept separate.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceVerified study/label regimen evidence is available. UK licensed oral semaglutide dosing — current formulation example. Open descriptive regimen evidence →
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
3structured study records
3outcome records
9linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
